HEADER TRANSCRIPTION ACTIVATOR 23-NOV-05 2F4B TITLE CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN OF HUMAN PPAR-GAMMA IN TITLE 2 COMPLEX WITH AN AGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: LIGAND BINDING DOMAIN; COMPND 5 SYNONYM: PPAR-GAMMA; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PGEX6P-1 KEYWDS PPAR, TRANSCRIPTION ACTIVATOR EXPDTA X-RAY DIFFRACTION AUTHOR I.L.LU,Y.H.PENG,N.MAHINDROO,H.P.HSIEH,S.Y.WU REVDAT 3 13-MAR-24 2F4B 1 REMARK REVDAT 2 24-FEB-09 2F4B 1 VERSN REVDAT 1 14-FEB-06 2F4B 0 JRNL AUTH N.MAHINDROO,C.C.WANG,C.C.LIAO,C.F.HUANG,I.L.LU,T.W.LIEN, JRNL AUTH 2 Y.H.PENG,W.J.HUANG,Y.T.LIN,M.C.HSU,C.H.LIN,C.H.TSAI,J.T.HSU, JRNL AUTH 3 X.CHEN,P.C.LYU,Y.S.CHAO,S.Y.WU,H.P.HSIEH JRNL TITL INDOL-1-YL ACETIC ACIDS AS PEROXISOME PROLIFERATOR-ACTIVATED JRNL TITL 2 RECEPTOR AGONISTS: DESIGN, SYNTHESIS, STRUCTURAL BIOLOGY, JRNL TITL 3 AND MOLECULAR DOCKING STUDIES JRNL REF J.MED.CHEM. V. 49 1212 2006 JRNL REFN ISSN 0022-2623 JRNL PMID 16451087 JRNL DOI 10.1021/JM0510373 REMARK 2 REMARK 2 RESOLUTION. 2.07 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.0 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.07 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 97.2 REMARK 3 NUMBER OF REFLECTIONS : 31791 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.222 REMARK 3 R VALUE (WORKING SET) : 0.219 REMARK 3 FREE R VALUE : 0.288 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1687 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.07 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.12 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2258 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 96.38 REMARK 3 BIN R VALUE (WORKING SET) : 0.2170 REMARK 3 BIN FREE R VALUE SET COUNT : 135 REMARK 3 BIN FREE R VALUE : 0.3180 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4356 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 39 REMARK 3 SOLVENT ATOMS : 140 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.69 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 1.14000 REMARK 3 B22 (A**2) : -0.95000 REMARK 3 B33 (A**2) : -0.19000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : -0.65000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.268 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.232 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.157 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 5.562 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.934 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.895 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4475 ; 0.021 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6033 ; 1.919 ; 2.000 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 540 ; 7.022 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 196 ;39.615 ;25.408 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 868 ;18.428 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 16 ;18.918 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 692 ; 0.149 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3265 ; 0.010 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 2215 ; 0.241 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 3095 ; 0.314 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 208 ; 0.194 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 76 ; 0.348 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 13 ; 0.194 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2827 ; 1.967 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1893 ; 3.830 ; 3.000 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1632 ; 5.096 ; 4.500 REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2F4B COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 29-NOV-05. REMARK 100 THE DEPOSITION ID IS D_1000035435. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 26-MAY-05 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SPRING-8 REMARK 200 BEAMLINE : BL12B2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : MONOCHROMATOR REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 4 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 34426 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.070 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 97.4 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.04600 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.07 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.14 REMARK 200 COMPLETENESS FOR SHELL (%) : 97.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.87 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.32 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 20% PEG3350, 0.2 SODIUM CITRATE, PH REMARK 280 8.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 291K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 44.32100 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THIS ENTRY CONTAINS THE CRYSTALLOGRAPHIC ASYMMETRIC UNIT REMARK 300 WHICH CONSISTS OF 2 CHAIN(A,B) REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 HIS A 266 CG HIS A 266 CD2 0.058 REMARK 500 THR B 238 C THR B 238 O 0.116 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 HIS A 266 CA - C - O ANGL. DEV. = -13.2 DEGREES REMARK 500 HIS A 266 O - C - N ANGL. DEV. = -11.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 LYS A 244 96.61 -177.99 REMARK 500 ASP A 260 6.26 -54.08 REMARK 500 LYS A 261 -76.31 -62.13 REMARK 500 ILE A 262 70.74 7.96 REMARK 500 LYS A 263 -34.81 -131.81 REMARK 500 HIS A 266 -152.66 -106.61 REMARK 500 PRO A 269 19.58 -60.80 REMARK 500 GLN A 271 99.07 -48.71 REMARK 500 GLN A 273 127.64 176.74 REMARK 500 SER A 274 30.29 -154.47 REMARK 500 LYS A 358 -76.46 -29.58 REMARK 500 THR A 461 -148.88 -83.75 REMARK 500 SER A 464 94.10 64.89 REMARK 500 ASP A 475 50.73 37.01 REMARK 500 THR B 238 -100.05 -92.66 REMARK 500 THR B 241 54.48 33.37 REMARK 500 ASP B 243 -49.19 -164.18 REMARK 500 SER B 245 145.39 -39.46 REMARK 500 LYS B 263 16.72 -140.63 REMARK 500 HIS B 266 -144.09 155.42 REMARK 500 SER B 274 0.32 -152.07 REMARK 500 SER B 342 71.46 44.00 REMARK 500 LEU B 393 54.34 -91.72 REMARK 500 LEU B 468 -37.29 -146.42 REMARK 500 TYR B 473 92.74 -53.79 REMARK 500 ASP B 475 13.14 55.04 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ARG A 357 LYS A 358 -146.75 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 HIS A 266 -28.78 REMARK 500 SER B 245 -17.27 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE EHA A 201 DBREF 2F4B A 207 477 UNP P37231 PPARG_HUMAN 235 505 DBREF 2F4B B 207 477 UNP P37231 PPARG_HUMAN 235 505 SEQRES 1 A 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 A 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 A 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 A 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 A 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 A 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 A 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 A 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 A 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 A 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 A 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 A 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 A 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 A 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 A 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 A 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 A 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 A 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 A 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 A 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 A 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR SEQRES 1 B 271 GLU SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR SEQRES 2 B 271 ASP SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS SEQRES 3 B 271 ALA ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER SEQRES 4 B 271 PRO PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY SEQRES 5 B 271 GLU ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN SEQRES 6 B 271 GLU GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY SEQRES 7 B 271 CYS GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR SEQRES 8 B 271 GLU TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP SEQRES 9 B 271 LEU ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS SEQRES 10 B 271 GLU ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS SEQRES 11 B 271 ASP GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR SEQRES 12 B 271 ARG GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP SEQRES 13 B 271 PHE MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN SEQRES 14 B 271 ALA LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE SEQRES 15 B 271 ALA VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU SEQRES 16 B 271 ASN VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU SEQRES 17 B 271 GLN ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SEQRES 18 B 271 SER SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR SEQRES 19 B 271 ASP LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU SEQRES 20 B 271 GLN VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS SEQRES 21 B 271 PRO LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR HET EHA A 201 39 HETNAM EHA (5-{3-[(6-BENZOYL-1-PROPYL-2-NAPHTHYL)OXY]PROPOXY}-1H- HETNAM 2 EHA INDOL-1-YL)ACETIC ACID HETSYN EHA 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY) HETSYN 2 EHA PROPOXY]INDOL-1-YL}ETHANOIC ACID FORMUL 3 EHA C33 H31 N O5 FORMUL 4 HOH *140(H2 O) HELIX 1 1 GLU A 207 PHE A 226 1 20 HELIX 2 2 THR A 229 GLY A 239 1 11 HELIX 3 3 ASP A 251 ASP A 260 1 10 HELIX 4 4 GLU A 276 SER A 302 1 27 HELIX 5 5 GLY A 305 LEU A 309 5 5 HELIX 6 6 ASP A 310 SER A 332 1 23 HELIX 7 7 ARG A 350 LEU A 356 1 7 HELIX 8 8 ARG A 357 ASP A 362 1 6 HELIX 9 9 MET A 364 ALA A 376 1 13 HELIX 10 10 ASP A 380 LEU A 393 1 14 HELIX 11 11 ASN A 402 HIS A 425 1 24 HELIX 12 12 GLN A 430 GLU A 460 1 31 HELIX 13 13 HIS A 466 LYS A 474 1 9 HELIX 14 14 GLU B 207 PHE B 226 1 20 HELIX 15 15 THR B 229 THR B 238 1 10 HELIX 16 16 ASP B 251 ASP B 260 1 10 HELIX 17 17 GLU B 276 SER B 302 1 27 HELIX 18 18 GLY B 305 LEU B 309 5 5 HELIX 19 19 ASP B 310 ALA B 331 1 22 HELIX 20 20 ARG B 350 SER B 355 1 6 HELIX 21 21 ARG B 357 ASP B 362 1 6 HELIX 22 22 MET B 364 ALA B 376 1 13 HELIX 23 23 ASP B 380 LEU B 393 1 14 HELIX 24 24 ASN B 402 HIS B 425 1 24 HELIX 25 25 GLN B 430 GLU B 460 1 31 SHEET 1 A 3 PHE A 247 ILE A 249 0 SHEET 2 A 3 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 A 3 GLY A 338 ILE A 341 -1 N VAL A 339 O MET A 348 SHEET 1 B 4 PHE B 247 ILE B 249 0 SHEET 2 B 4 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 B 4 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 SHEET 4 B 4 MET B 334 ASN B 335 -1 N ASN B 335 O GLY B 338 SITE 1 AC1 17 LEU A 255 GLU A 259 ARG A 280 PHE A 282 SITE 2 AC1 17 GLY A 284 CYS A 285 GLN A 286 SER A 289 SITE 3 AC1 17 TYR A 327 LEU A 330 ILE A 341 MET A 348 SITE 4 AC1 17 PHE A 363 MET A 364 LYS A 367 HIS A 449 SITE 5 AC1 17 TYR A 473 CRYST1 55.967 88.642 57.878 90.00 90.01 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017868 0.000000 0.000003 0.00000 SCALE2 0.000000 0.011281 0.000000 0.00000 SCALE3 0.000000 0.000000 0.017278 0.00000